In a fresh corporate presentation, Evotec has provided concrete new details regarding costs, structure, and liquidity as part of its ongoing strategic transformation. The update brings greater clarity to the company’s “Priority Reset” program, designed to significantly reduce its cost base, and quantifies the financial impact of its asset sale to Sandoz. The disclosures set the stage for a key upcoming event: the financial forecast scheduled for April.
Financial Strategy: Monetization and Efficiency Gains
Central to Evotec’s mid-term value creation plan are four key drivers. Management aims to achieve stronger growth with improved earnings quality, boost operational efficiency through cost reductions, more aggressively monetize its Just‑Evotec‑Biologics technology platform, and generate additional revenue from milestone payments and royalties tied to its proprietary pipeline.
The company’s pipeline itself now contains over 100 assets, approximately 60% of which are partnered. Evotec projects that cumulative cash inflows from this segment could reach €500 million by 2028. This strategic shift is intended to diversify the revenue base away from purely research-driven expenditures and toward more predictable payment streams.
Tangible Cost Savings and Workforce Reductions
Evotec reports measurable progress on its cost-saving initiatives. For 2025, the group anticipates achieving structural cost reductions exceeding €60 million, a figure the presentation notes is higher than originally targeted.
Should investors sell immediately? Or is it worth buying Evotec?
A major component of this effort is a reduction in headcount. Within the “Discovery & Preclinical Development” segment, the workforce was cut by approximately 600 full-time positions between March 2024 and June 2025. This move supports a strategic pivot to a less capital-intensive model, which involves deploying less capital into owned research infrastructure and focusing more on higher-margin revenue sources.
Sandoz Transaction Bolsters Liquidity Profile
Additional financial resources are expected from the divestment of the Just‑Evotec‑Biologics site in Toulouse to Sandoz. The company has confirmed an upfront cash payment of approximately $350 million. Furthermore, Evotec anticipates receiving over $300 million in additional transition revenues between 2026 and 2028, supplemented by forthcoming license fees from a biosimilar portfolio.
Despite these detailed updates, market uncertainty continues to weigh on the equity. Over a 30-day period, the shares have declined 14.07%, with a closing price on Friday of €5.46. This places the stock notably below its 50-day moving average of €6.07.
Investors’ next concrete milestone is set for 8 April 2026, with the publication of the full annual report. This date is also when the financial forecast for the current business year will be released. The report will provide critical insight into how substantially the cost savings and Toulouse-derived revenues are reflected in the company’s formal planning.
Ad
Evotec Stock: Buy or Sell?! New Evotec Analysis from March 7 delivers the answer:
The latest Evotec figures speak for themselves: Urgent action needed for Evotec investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 7.
Evotec: Buy or sell? Read more here...
